Could a simple scan unlock better heart treatment?

NCT ID NCT05776212

Recruiting now Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new PET scan technique to better track heart damage in people with a condition called ATTR-CM, a progressive heart muscle disease. Researchers will scan 140 participants to see if the imaging can show how well treatments are working. The goal is to improve monitoring and help doctors choose the best therapies for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-fluoride PET scan (imaging tracer)
What this could lead to: If successful, this imaging technique could help doctors see how well treatments are working for ATTR-CM heart disease, leading to more personalized and cost-effective care.
What could go wrong: This is an early-stage imaging study, not a treatment trial. The new scan method may not prove accurate enough to replace current monitoring, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis amyloidosis heart failure hypertrophic cardiomyopathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTR-CM

Contacts and locations

Locations

University Medical Centre Groningen
RECRUITING

Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.